PATENT CLAIM ANALYSIS

Application Number: 15979041
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "402000"]

Abstract:
The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

Claim (Index 38):
The method of  claim 37  wherein the drug therapy comprises the administration of bisantrene and wherein the chemosensitization or chemopotentiation is selected from the group consisting of:\n (a) use as a chemosensitizer or chemopotentiator in combination with topoisomerase inhibitors; \n (b) use as a chemosensitizer or chemopotentiator in combination with fraudulent nucleosides; \n (c) use as a chemosensitizer or chemopotentiator in combination with fraudulent nucleotides; \n (d) use as a chemosensitizer or chemopotentiator in combination with thymidylate synthetase inhibitors; \n (e) use as a chemosensitizer or chemopotentiator in combination with signal transduction inhibitors; \n (f) use as a chemosensitizer or chemopotentiator in combination with cisplatin or platinum analogs; \n (g) use as a chemosensitizer or chemopotentiator in combination with alkylating agents; \n (h) use as a chemosensitizer or chemopotentiator in combination with anti-tubulin agents; \n (i) use as a chemosensitizer in combination with antimetabolites; \n (j) use as a chemosensitizer or chemopotentiator in combination with berberine; \n (k) use as a chemosensitizer or chemopotentiator in combination with apigenin; \n (l) use as a chemosensitizer or chemopotentiator in combination with colchicine or analogs of colchicine; \n (m) use as a chemosensitizer or chemopotentiator in combination with genistein; \n (n) use as a chemosensitizer or chemopotentiator in combination with etoposide; \n (o) use as a chemosensitizer or chemopotentiator in combination with cytarabine; \n (p) use as a chemosensitizer or chemopotentiator in combination with camptothecins; \n (q) use as a chemosensitizer or chemopotentiator in combination with vinca alkaloids; \n (r) use as a chemosensitizer or chemopotentiator in combination with 5-fluorouracil; \n (s) use as a chemosensitizer or chemopotentiator in combination with curcumin; \n (t) use as a chemosensitizer or chemopotentiator in combination with rosmarinic acid; and \n (u) use as a chemosensitizer or in combination with mitoguazone.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 93.0
- Lexical Diversity: 1.31579
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14907728', '14907729', '13817096', '14753911', '14245738']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7894993227597871
- 35 USC 102 Novelty (BERT): 0.5336972288146506
- Combined Prediction Score: 0.7639191133652734
- Mean Citation Score: 267.787678
- Max Citation Score: 348.62634
- Similarity Product: 251.3466092826319

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test